Our Research

Discover our recent findings, catch up with news, and review in-depth resources.

Resolian optimised its LC-MS extractables and leachables SST mixture from 15 to fewer than 10 components, improving robustness without sacrificing USP coverage.

Case Studies

Leaner, More Reliable: Building a Fit-for-Purpose LC-MS System Suitability Mixture for Extractables and Leachables Screening

Resolian’s Analytical Sciences team developed a simplified, USP-aligned system suitability test mixture for non-targeted LC-HRAMS extractables and leachables screening, reducing component count from fifteen to fewer than ten while maintaining coverage of all key USP stimulus attributes.
Read more
ADA Assay Development for GalNAc-siRNA Therapeutics | MSD and Gyrolab Platform Comparison | Resolian

Case Studies

Immunogenicity in the Age of siRNA: Developing ADA Assays for GalNAc-Conjugated siRNA Therapeutics

Resolian developed and validated an MSD-based bridging ECLIA method for analysing anti-drug antibodies against a GalNAc-conjugated siRNA therapeutic, evaluating both MSD and Gyrolab platforms for different GalNAc-conjugated siRNA therapeutics and providing a practical framework for immunogenicity assay development in this novel modality.
Read more
Plasma Protein Binding Assessment for Highly Protein-Bound Compounds | ICH M12 | Resolian

Case Studies

Measuring What Matters: High-Precision Plasma Protein Binding Assessment for Highly Bound Compounds Under ICH M12

Resolian developed high-precision LC-MS/MS methods and optimised equilibrium dialysis workflows for plasma protein binding assessment of highly protein-bound compounds, Supporting ICH M12 regulatory expectations across five species.
Read more
Resolian Sandwich Analytical Sciences Lab Tour

Videos

Resolian Sandwich UK Analytical Sciences Lab Tour

Take a virtual tour of Resolian’s Sandwich lab: analytical and materials science expertise spanning solid state, physical properties, and foreign matter analysis.
Read more
Solving Carboplatin: A Novel LC-MS/MS Assay for Intact Drug Quantitation in Human Plasma

Case Studies

Solving Carboplatin: A Novel LC-MS/MS Assay for Intact Drug Quantitation in Human Plasma

Resolian developed and validated (following ICH-M10) a high-throughput and robust LC MS/MS method for quantifying intact carboplatin in human plasma, overcoming long-standing challenges around isotopic interference, protein binding, and chromatographic retention.
Read more
Effect of Particle Size Reduction on the Surface Energy of Sucrose | Resolian

Case Studies

Surface Energy and Sucrose: Why Milling Method Matters More Than Particle Size

How does milling method affect pharmaceutical powder surfaces? Resolian’s iGC-SEA analysis of sucrose reveals that processing route influences surface energy more significantly than particle size alone.
Read more
Scroll to Top
Zhao. Resolian Bioanalytics and Analytical Sciences.

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett. Resolian Bioanalytics and Analytical Sciences.

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.